Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Coexistence of lymphoproliferative and myeloproliferative neoplasms with simultaneous CALR and JAK2 V617F mutations.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Author-Supplied Keywords:
      CALR
      JAK2
      Lymphoproliferative neoplasm
      MPNs
    • Abstract:
      BACKGROUND: Hematopoietic malignancies are a group of blood cell disorders characterized by abnormal hematopoietic proliferation. OBJECTIVE: The identification of specific clinicopathologic characteristics and tumor-related gene status provides critical information on potential therapeutic targets. METHODS: The specimens were tested with immunohistochemistry, flow cytometry, RT-PCR and fragment analysis. RESULTS: In this study, a patient with a long history of tobacco use was reported with a diagnosis of simultaneous low-grade B-cell lymphoproliferative disorder (LPD) and myeloproliferative neoplasm (MPN). Mutational analysis revealed that JAK2 V617F mutation and CALR mutation with 52bp deletion were present in this patient. CONCLUSION: These results suggest that lymphoproliferative and myeloproliferative neoplasms may coexist, although the pathogenetic mechanism of coexisting hematologic requires further investigation. Additionally, the data indicate that JAK2 V617F and CALR mutations are not mutually exclusive and the actual frequency of simultaneous JAK2 V617F and CALR mutations is unknown. Whether the coexistence of these mutations imposes any biological or clinical significance awaits further investigation. [ABSTRACT FROM AUTHOR]
    • Abstract:
      Copyright of Cancer Biomarkers is the property of IOS Press and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
    • Author Affiliations:
      1Integrated Oncology, Laboratory Corporation of America® Holdings, 521 W. 57th St., New York, NY 10019, USA
    • ISSN:
      1574-0153
    • Accession Number:
      10.3233/CBM-160652
    • Accession Number:
      120665013
  • Citations
    • ABNT:
      HAI-SU YANG. Coexistence of lymphoproliferative and myeloproliferative neoplasms with simultaneous CALR and JAK2 V617F mutations. Cancer Biomarkers, [s. l.], v. 17, n. 4, p. 383–389, 2016. DOI 10.3233/CBM-160652. Disponível em: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=120665013&custid=s8280428. Acesso em: 3 jul. 2020.
    • AMA:
      Hai-Su Yang. Coexistence of lymphoproliferative and myeloproliferative neoplasms with simultaneous CALR and JAK2 V617F mutations. Cancer Biomarkers. 2016;17(4):383-389. doi:10.3233/CBM-160652.
    • AMA11:
      Hai-Su Yang. Coexistence of lymphoproliferative and myeloproliferative neoplasms with simultaneous CALR and JAK2 V617F mutations. Cancer Biomarkers. 2016;17(4):383-389. doi:10.3233/CBM-160652
    • APA:
      Hai-Su Yang. (2016). Coexistence of lymphoproliferative and myeloproliferative neoplasms with simultaneous CALR and JAK2 V617F mutations. Cancer Biomarkers, 17(4), 383–389. https://doi.org/10.3233/CBM-160652
    • Chicago/Turabian: Author-Date:
      Hai-Su Yang. 2016. “Coexistence of Lymphoproliferative and Myeloproliferative Neoplasms with Simultaneous CALR and JAK2 V617F Mutations.” Cancer Biomarkers 17 (4): 383–89. doi:10.3233/CBM-160652.
    • Harvard:
      Hai-Su Yang (2016) ‘Coexistence of lymphoproliferative and myeloproliferative neoplasms with simultaneous CALR and JAK2 V617F mutations’, Cancer Biomarkers, 17(4), pp. 383–389. doi: 10.3233/CBM-160652.
    • Harvard: Australian:
      Hai-Su Yang 2016, ‘Coexistence of lymphoproliferative and myeloproliferative neoplasms with simultaneous CALR and JAK2 V617F mutations’, Cancer Biomarkers, vol. 17, no. 4, pp. 383–389, viewed 3 July 2020, .
    • MLA:
      Hai-Su Yang. “Coexistence of Lymphoproliferative and Myeloproliferative Neoplasms with Simultaneous CALR and JAK2 V617F Mutations.” Cancer Biomarkers, vol. 17, no. 4, Oct. 2016, pp. 383–389. EBSCOhost, doi:10.3233/CBM-160652.
    • Chicago/Turabian: Humanities:
      Hai-Su Yang. “Coexistence of Lymphoproliferative and Myeloproliferative Neoplasms with Simultaneous CALR and JAK2 V617F Mutations.” Cancer Biomarkers 17, no. 4 (October 2016): 383–89. doi:10.3233/CBM-160652.
    • Vancouver/ICMJE:
      Hai-Su Yang. Coexistence of lymphoproliferative and myeloproliferative neoplasms with simultaneous CALR and JAK2 V617F mutations. Cancer Biomarkers [Internet]. 2016 Oct [cited 2020 Jul 3];17(4):383–9. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=120665013&custid=s8280428